This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Jayex Technology Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Jayex Technology's earnings have been declining at an average annual rate of -38.9%, while the Healthcare Services industry saw earnings growing at 13.5% annually. Revenues have been declining at an average rate of 13.5% per year.

Belangrijke informatie

-38.9%

Groei van de winst

-30.1%

Groei van de winst per aandeel

Healthcare Services Groei van de industrie	42.6%
Inkomstengroei	-13.5%
Rendement op eigen vermogen	n/a
Nettomarge	-103.1%
Laatste winstupdate	31 Dec 2023

Recente prestatie-updates uit het verleden

Recent updates

Opbrengsten en kosten

Hoe Jayex Technology geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

CHIA:JTL Opbrengsten, kosten en inkomsten (AUD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven
31 Dec 23	4	-4	2
30 Sep 23	4	-5	2
30 Jun 23	4	-6	2
31 Mar 23	4	-6	2
31 Dec 22	5	-6	2
30 Sep 22	5	-5	2
30 Jun 22	5	-3	2
31 Mar 22	5	-4	2
31 Dec 21	5	-4	2
30 Sep 21	4	-3	2
30 Jun 21	4	-3	1
31 Mar 21	5	-2	2
31 Dec 20	6	-1	2
30 Sep 20	6	-1	1
30 Jun 20	7	0	1
31 Mar 20	7	-1	1
31 Dec 19	7	-1	1
30 Sep 19	7	-1	1
30 Jun 19	7	-1	2
31 Mar 19	7	-1	2
31 Dec 18	7	-1	2
30 Sep 18	7	-1	2
30 Jun 18	7	-1	2
31 Mar 18	7	-2	2
31 Dec 17	8	-2	2
30 Sep 17	7	-4	2
30 Jun 17	7	-5	2
31 Mar 17	8	-5	2
31 Dec 16	9	-5	2
30 Jun 16	7	-4	2
31 Mar 16	4	-4	1
31 Dec 15	2	-3	1
30 Jun 15	1	-1	1
30 Jun 14	0	0	0

Kwaliteitswinsten: JTL is currently unprofitable.

Groeiende winstmarge: JTL is currently unprofitable.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: JTL is unprofitable, and losses have increased over the past 5 years at a rate of 38.9% per year.

Versnelling van de groei: Unable to compare JTL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: JTL is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (7.1%).

Rendement op eigen vermogen

Hoge ROE: JTL's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

This company listing is no longer active

Jayex Technology Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

First half 2023 earnings released: AU$0.003 loss per share (vs AU$0.004 loss in 1H 2022)

Full year 2022 earnings released: AU$0.024 loss per share (vs AU$0.019 loss in FY 2021)

First half 2022 earnings released: AU$0.004 loss per share (vs AU$0.008 loss in 1H 2021)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Full year 2020 earnings released: AU$0.004 loss per share (vs AU$0.006 loss in FY 2019)

Full year 2020 earnings released: AU$0.004 loss per share (vs AU$0.006 loss in FY 2019)

Recent updates

High number of new directors

Jayex Technology Limited Announces Board Changes

Jayex Technology Limited, Annual General Meeting, Jul 04, 2024

Less than half of directors are independent

Jayex Technology Limited Announces Directorate Changes

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

First half 2023 earnings released: AU$0.003 loss per share (vs AU$0.004 loss in 1H 2022)

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Full year 2022 earnings released: AU$0.024 loss per share (vs AU$0.019 loss in FY 2021)

Jayex Technology Limited Announces Resignation of Nathan Woodard as Chief Financial Officer, Effective January 31, 2023

No independent directors

No independent directors

Jayex Technology Limited Announces Resignation of Michael Chan as Non-Executive Director

No independent directors

No independent directors

Jayex Technology Limited Appoints Robert Hadle as Chief Executive Officer, Effective 3 October 2022

First half 2022 earnings released: AU$0.004 loss per share (vs AU$0.008 loss in 1H 2021)

No independent directors

No independent directors

No independent directors

Jayex Technology Limited, Annual General Meeting, May 26, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

No independent directors

Jayex Technology Limited has completed a Follow-on Equity Offering in the amount of AUD 0.572723 million.

Jayex Healthcare Limited announced that it expects to receive AUD 0.572723 million in funding

Vitalhub Corp. (TSXV:VHI) completed the acquisition of Assets of On-premises Acute (hospital) queue management business of Jayex Healthcare Limited (ASX:JHL).

Full year 2020 earnings released: AU$0.004 loss per share (vs AU$0.006 loss in FY 2019)

Jayex Healthcare Limited, Annual General Meeting, May 27, 2021

Full year 2020 earnings released: AU$0.004 loss per share (vs AU$0.006 loss in FY 2019)

MyFiziq Limited Signs Binding Term Sheet with Jayex Healthcare Limited

Jayex Healthcare Limited announced that it expects to receive AUD 0.7 million in funding

First half earnings released

Jayex Healthcare Limited Announces Resignation of Nick Fernando as Group Chief Executive Officer Effective 25 July 2020

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Rendement op eigen vermogen

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden